title: Ruboxistaurin (Eli Lilly).
abstract: Eli Lilly & Co is developing the protein kinase C (PKC)-b inhibitor ruboxistaurin, the lead compound from a series of 14-membered macrocycles, for the potential treatment of diabetic retinopathy, diabetic peripheral neuropathy and macular edema.
authors.affiliation: 102-711 West 17th Avenue, Vancouver, BC V5Z 1V1, Canada. editor@greyowltutor.com
authors.forename: Glen D
authors.initials: GD
authors.lastname: Wheeler
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000201:enzymology; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D011493:Protein Kinase C